{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:37:15Z","timestamp":1760060235297,"version":"build-2065373602"},"reference-count":19,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"East German Study Group for Hematology and Oncology (OSHO)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Purpose: Evaluate long-term immunogenicity and its association with the number of vaccines and breakthrough infections in patients with hematologic malignancies compared to a healthy cohort. Methods: This study is an amendment of a multicenter study (DRKS00027372) which described the upsurge of anti-spike-IgGs on day 120 from a blunted day-35 response in patients with hematologic neoplasms. In this amendment, 191 individuals from the original study (patients with myeloid and lymphoid neoplasms and controls) were followed beyond month 12 after first SARS-CoV-2-vaccination. The long-term humoral and cellular responses and their correlation with the number of vaccines were studied. Results: After a median follow-up of 18 months, a median of three vaccinations (range 1\u20135) were given. Antibody levels did not correlate with the number of vaccinations (\u22642 versus \u22653) (p = 0.3). With a median of 5274 U\/mL anti-spike-IgGs, the inferior day-120 antibody response in patients with lymphoid neoplasms was no longer detected. Breakthrough SARS-CoV-2-infections, mostly mild, occurred in 67% of controls and 46% of patients. Patients with lymphoid neoplasms with two vaccinations did not have more infections compared to patients with more doses (p = 0.4). There was a significant decline in the spike-specific T-cell response for CovCD4+ and CovCD8+ (p &lt; 0.001). On last assessment, 33% of individuals lost their day-120 CovCD4+-positive response (p &lt; 0.001). There was no correlation between the number of vaccinations and cellular immune response in patients and controls (p = 0.3). Conclusions: In this study, breakthrough infections were high despite repeated boosting, which by itself does not lead to an upsurge in the cellular immune response in the majority of patients.<\/jats:p>","DOI":"10.3390\/cancers17162674","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T11:31:37Z","timestamp":1755516697000},"page":"2674","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Immune Response to SARS-CoV-2 Vaccination in Hematologic Malignancies: An Update of the ImV-HOng Trial of the East German Study Group for Hematology and Oncology"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3856-7956","authenticated-orcid":false,"given":"Susann","family":"Schulze","sequence":"first","affiliation":[{"name":"Krukenberg Cancer Center Halle, University Hospital Halle (Saale), 06120 Halle (Saale), Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Jotschke","sequence":"additional","affiliation":[{"name":"Krukenberg Cancer Center Halle, University Hospital Halle (Saale), 06120 Halle (Saale), Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1048-3638","authenticated-orcid":false,"given":"Robby","family":"Engelmann","sequence":"additional","affiliation":[{"name":"Clinic III-Hematology, Oncology, and Palliative Care, Rostock University Medical Center, 18057 Rostock, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2660-4921","authenticated-orcid":false,"given":"Beatrice","family":"Ludwig-Kraus","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Unit II LM-CC, University Hospital Halle (Saale), 06120 Halle (Saale), Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4354-9952","authenticated-orcid":false,"given":"Frank Bernhard","family":"Kraus","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Unit II LM-CC, University Hospital Halle (Saale), 06120 Halle (Saale), Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6162-515X","authenticated-orcid":false,"given":"Nadja","family":"Jaekel","sequence":"additional","affiliation":[{"name":"University Clinic and Outpatient Clinic for Internal Medicine IV, University Hospital Halle (Saale), 06120 Halle (Saale), Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Zahn","sequence":"additional","affiliation":[{"name":"Krukenberg Cancer Center Halle, University Hospital Halle (Saale), 06120 Halle (Saale), Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Junghanss","sequence":"additional","affiliation":[{"name":"Clinic III-Hematology, Oncology, and Palliative Care, Rostock University Medical Center, 18057 Rostock, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3603-761X","authenticated-orcid":false,"given":"Sebastian","family":"B\u00f6ttcher","sequence":"additional","affiliation":[{"name":"Clinic III-Hematology, Oncology, and Palliative Care, Rostock University Medical Center, 18057 Rostock, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5009-2239","authenticated-orcid":false,"given":"Haifa Kathrin","family":"Al-Ali","sequence":"additional","affiliation":[{"name":"Krukenberg Cancer Center Halle, University Hospital Halle (Saale), 06120 Halle (Saale), Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13045-022-01233-3","article-title":"Serologic response following SARS-COV2 vaccination in patients with cancer: A systematic review and meta-analysis","volume":"15","author":"Sakuraba","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.clml.2024.01.004","article-title":"Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy: A Prospective Cohort Study","volume":"24","author":"Hillyer","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_3","unstructured":"Centers for Disease Control and Prevention: Vaccines & Immunizations (2025, February 22). Use of COVID-19 Vaccines in the United States. Interim Clinical Considerations, Available online: https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/covid-19-vaccines-us.html."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Jotschke, S., Schulze, S., Jaekel, N., Ludwig-Kraus, B., Engelmann, R., Kraus, F.B., Zahn, C., Nedlitz, N., Prange-Krex, G., and Mohm, J. (2022). Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of the East German Study Group for Hematology and Oncology (OSHO). Cancers, 14.","DOI":"10.3390\/cancers14061544"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/bloodadvances.2022009054","article-title":"Vector-based SARS-CoV-2 vaccination is associated with improved T-cell responses in hematological neoplasia","volume":"7","author":"Engelmann","year":"2023","journal-title":"Blood Adv."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","article-title":"Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy","volume":"27","author":"Apostolidis","year":"2021","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1200\/JCO.24.00032","article-title":"Vaccination of Adults with Cancer: ASCO Guideline","volume":"42","author":"Kamboj","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"114271","DOI":"10.1016\/j.jviromet.2021.114271","article-title":"Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassay","volume":"297","author":"Riester","year":"2021","journal-title":"J. Virol. Methods"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/S2666-5247(21)00266-4","article-title":"WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: Call for urgent action by the scientific community","volume":"3","author":"Knezevic","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_10","unstructured":"WHO International Institute for Biological Standards and Control (2025, June 01). First WHO International Standard Anti-SARS-CoV-2 Immunoglobulin (Human). Version 2.0. NIBSC Code: 20\/136. Counter = 1213. Available online: https:\/\/www.nibsc.org\/products\/brm_product_catalogue\/detail_page.aspx?catid=20\/136."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/leu.2012.122","article-title":"EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols","volume":"26","author":"Kalina","year":"2012","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/cyto.a.22319","article-title":"A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC\/CRI)","volume":"83","author":"McNeil","year":"2013","journal-title":"Cytom. A"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/cyto.a.24244","article-title":"Gating Harmonization Guidelines for Intracellular Cytokine Staining Validated in Second International Multiconsortia Proficiency Panel Conducted by Cancer Immunotherapy Consortium (CIC\/CRI)","volume":"99","author":"Price","year":"2021","journal-title":"Cytom. A"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","article-title":"BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans","volume":"595","author":"Sahin","year":"2021","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41591-021-01464-w","article-title":"Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19\/mRNA vaccination","volume":"27","author":"Schmidt","year":"2021","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Karmacharya, A., Rai, K., Siwakoti, S., Khanal, B., and Bhattarai, N.R. (2024). COVID-19 breakthrough infections in vaccinated individuals at BPKIHS, Nepal. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-024-09902-z"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/infdis\/jiv748","article-title":"Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose","volume":"214","author":"Bruce","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1038\/s41467-021-25167-5","article-title":"Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern","volume":"12","author":"Skelly","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.exphem.2012.10.004","article-title":"Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I\/II dose-finding study","volume":"41","author":"Wolschke","year":"2013","journal-title":"Exp. Hematol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/16\/2674\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:29:06Z","timestamp":1760034546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/16\/2674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":19,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["cancers17162674"],"URL":"https:\/\/doi.org\/10.3390\/cancers17162674","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2025,8,16]]}}}